Download presentation
Presentation is loading. Please wait.
Published byRidwan Susanto Widjaja Modified over 6 years ago
1
Ask Dr Durie – Doctors’ Edition: Proteasome Inhibitors in Multiple Myeloma
2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
3
Ask Dr Durie – Doctors’ Edition: Proteasome Inhibitors in Multiple Myeloma: Agenda
4
Proteasome Inhibitors and MM Treatment
5
FDA-Approved Proteasome Inhibitors
6
How Are Proteasome Inhibitors Used in the Frontline Setting?
7
Proteasome Inhibitors as Initial Therapy
8
SWOG S0777: RVD vs RD
9
Components of MM Treatment
10
PETHEMA/GEM: VTD vs TD vs VBMCP/VBAD/B
11
Reducing the Incidence of Treatment-Related PN With Bortezomib
12
CyBorD in ND MM
13
Overview of Induction Regimens for Transplant-Eligible Patients With ND MM
14
Proteasome Inhibitors in Transplant-Ineligible Patients
15
VISTA: VMP vs MP in Transplant-Ineligible MM
16
ALCYONE: VMP + Daratumumab as Induction Therapy in Transplant-Ineligible MM
17
Bortezomib as Maintenance Therapy in MM
18
Alternative Proteasome Inhibitors in ND MM: Carfilzomib
19
Alternative Proteasome Inhibitors in ND MM: Ixazomib
20
Does High-Risk Disease Impact Proteasome Inhibitor-Based Therapy Selection?
21
Staging MM
22
Selecting Initial Therapy for High-Risk MM
23
EMN02/HO95: Tandem Transplants
24
KRD as Initial Treatment in ND MM
25
Maintenance Therapy for High-Risk MM
26
Phase 3 Trials of Proteasome Inhibitor-Based Therapy in R/R MM
27
How Are Proteasome Inhibitors Used in the Relapsed Setting?
28
Therapy Considerations
29
Selecting a Regimen in R/R MM
30
Recent Phase 3 Trials in R/R MM
31
Proteasome Inhibitors in Practice: R/R MM
32
What Are the Adverse Events Associated With Proteasome Inhibitors and How are They Managed?
33
Antiviral Prophylaxis
34
Peripheral Neuropathy With Proteasome Inhibitors
35
Managing Peripheral Neuropathy
36
Cardiopulmonary Issues
37
Carfilzomib in Patients With Cardiac History
38
Optimizing Communication With Patients
39
Ask Dr Durie – Doctors’ Edition: Proteasome Inhibitors in Multiple Myeloma
40
FDA-Approved Proteasome Inhibitors
41
Key Takeaways
42
Optimizing Communication With Patients
43
Abbreviations
44
Abbreviations (cont)
45
Abbreviations (cont)
46
Abbreviations (cont)
47
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.